全身性強皮症(強皮症)の疫学的予測

◆英語タイトル:EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024
◆商品コード:GDHCER109-15
◆発行会社(調査会社):GlobalData
◆発行日:2015年12月9日
◆ページ数:68
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,995 ⇒換算¥439,450見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD7,990 ⇒換算¥878,900見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD11,985 ⇒換算¥1,318,350見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、全身性強皮症(強皮症)の疫学的市場予測について調査・分析し、以下の構成でお届けいたします。

・イントロダクション
・全身性強皮症(強皮症)の概要
・リスク要因及び併存症
・主要地域の動向
・疫学的予測方法
・全身性強皮症(強皮症)の疫学的予測結果(有病率など)
・考察(結論、分析の限界・強み)
【レポートの概要】

EpiCast Report: Systemic Sclerosis (Scleroderma) – Epidemiology Forecast to 2024

Summary

Systemic sclerosis (SSc) is an autoimmune disease of the connective tissue, and is characterized by excessive fibrosis, vascular alterations, and the proliferation of antibodies against numerous cellular antigens. SSc mainly affects those ages 40-50 years, and occurs predominantly in women, with a female-to-male sex ratio of 4:1. There are two main forms of the disease: limited and diffuse cutaneous scleroderma (lSSc and dSSc, respectively). lSSc primarily affects the hands, arms, and face, whereas dSSc affects a vast area of the skin and involves one or more internal organs. Raynaud’s phenomenon (RP) develops in the majority of both forms of SSc. The primary cause of death in both lSSC and dSSc is involvement of the lungs.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of SSc for ages 18 years and older will increase from 131,129 cases in 2014 to 141,499 cases in 2024. GlobalData epidemiologists forecast that in 2024, the US will have the highest number of diagnosed prevalent cases of SSc, with 95,992 cases, accounting for 68% of cases in the 7MM. In the 7MM in 2014, the group age 50-59 years had the highest proportion of diagnosed prevalent cases of SSc at 25.51%. In 2014, the diagnosed prevalent cases of SSc in the 7MM were lower in men compared with women with 15.36% diagnosed prevalent cases in men and 84.64% diagnosed prevalent cases in women. Of all the diagnosed prevalent cases of SSc in the 7MM in 2014, more had experienced RP (126,151 cases) than a DU (67,099 cases). In each of the 7MM, approximately 95% of the diagnosed prevalent SSc cases had experienced RP. In all markets other than France, Germany, and Italy, 70.50% of the diagnosed prevalent cases of SSc were lSSc. In the 7MM in 2014, 18,395 of the diagnosed prevalent cases of dSSc had ILD, and 6,679 of the diagnosed prevalent cases of dSSc had kidney disease.

GlobalData epidemiologists utilized comprehensive, country-specific data from registries and peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the diagnosed prevalent cases of SSc. In this analysis, GlobalData epidemiologists provide detailed, clinically relevant segmentations for the diagnosed prevalent cases of SSc. Finally, the same forecast methodology was used across the 7MM, thereby allowing for meaningful global comparisons of the diagnosed prevalent cases of SSc across these markets.

Scope

- The Systemic Sclerosis (SSc) EpiCast Report provides an overview of the risk factors and global trends of SSc in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of SSc diagnosed prevalent cases in these markets, segmented by age, sex, presence of Raynaud’s phenomenon (RP), presence of digital ulcers (DUs), limited systemic sclerosis (ISSc), and diffuse systemic sclerosis (dSSc). The diagnosed prevalent cases of dSSc are further segmented into cases with pulmonary fibrosis (PF)/interstitial lung disease (ILD) and kidney disease.
- The SSc epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The SSc EpiCast report will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global SSc market.
- Quantify patient populations in the global SSc market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SSc therapeutics in each of the markets covered.
- Identify the percentage of SSc diagnosed prevalent cases by disease type.

【レポートの目次】

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 9
3.3 Global Trends 12
3.4 Forecast Methodology 14
3.4.1 Sources Used 15
3.4.2 Sources Not Used 30
3.4.3 Forecast Assumptions and Methods 30
3.5 Epidemiological Forecast for SSc (2014-2024) 43
3.5.1 Diagnosed Prevalent Cases of SSc 43
3.5.2 Age-Specific Diagnosed Prevalent Cases of SSc 44
3.5.3 Sex-Specific Diagnosed Prevalent Cases of SSc 47
3.5.4 Age-Standardized Prevalence of SSc 48
3.5.5 Diagnosed Prevalent Cases of SSc with RP and SSc with DU 49
3.5.6 SSc Segmented into lSSc and dSSc 51
3.5.7 Sex-Specific Diagnosed Prevalent Cases of lSSc 52
3.5.8 Sex-Specific Diagnosed Prevalent Cases of dSSc 53
3.5.9 Diagnosed Prevalent Cases of dSSc with ILD and Cases with Kidney Disease 54
3.6 Discussion 56
3.6.1 Epidemiological Forecast Insight 56
3.6.2 Limitations of the Analysis 56
3.6.3 Strengths of the Analysis 57
4 Appendix 58
4.1 Bibliography 58
4.2 About the Authors 63
4.2.1 Epidemiologists 63
4.2.2 Reviewers 64
4.2.3 Global Director of Therapy Analysis and Epidemiology 65
4.2.4 Global Head of Healthcare 65
4.3 About GlobalData 66
4.4 About EpiCast 66
4.5 Disclaimer 67

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for SSc 11
Table 2: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of SSc 15
Table 3: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of SSc with RP 16
Table 4: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of SSc with DU 17
Table 5: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of SSc, Segmented by lSSc and dSSc 18
Table 6: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of dSSc with ILD 19
Table 7: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of dSSc with Kidney Disease 20
Table 8: 7MM, Diagnosed Prevalent Cases of SSc, Both Sexes, Age ≥18 Years, Select Years, 2014-2024 43
Table 9: 7MM, Age-Specific Diagnosed Prevalent Cases of SSc, Both Sexes, N (Row%), 2014 45
Table 10: 7MM, Sex-Specific Diagnosed Prevalent Cases of SSc, Age ≥18 Years, N (Row %), 2014 47
Table 11: 7MM, Diagnosed Prevalent Cases of SSc with RP, and SSc with DU, Both Sexes, Age ≥18 Years, N (% of Diagnosed Prevalent SSc Cases), 2014 50
Table 12: 7MM, Sex-Specific Diagnosed Prevalent Cases of lSSc, Age ≥18 Years, N (Row %), 2014 53
Table 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of dSSc, Ages ≥18 Years, N (Row %), 2014 54
Table 14: 7MM, Diagnosed Prevalent Cases of dSSc with ILD and dSSc with Kidney Disease, Both Sexes, Age ≥15 Years, N (% of Diagnosed Prevalent dSSc Cases), 2014 55

1.2 List of Figures
Figure 1: Case Flow Map of the Diagnosed Prevalent Cases of SSc 21
Figure 2: 7MM, Diagnosed Prevalent Cases of SSc, Both Sexes, Age ≥18 Years, Selected Years, 2014-2024 44
Figure 3: 7MM, Age-Specific Diagnosed Prevalent Cases of SSc, Both Sexes, 2014 46
Figure 4: 7MM, Sex-Specific Diagnosed Prevalent Cases of SSc, Age ≥18 Years, 2014 48
Figure 5: 7MM, Age-Standardized Diagnosed Prevalence of SSc, 2014 49
Figure 6: 7MM, Diagnosed Prevalent Cases of SSc with RP and SSc with DU, Both Sexes, Age ≥18 Years, N, 2014 51
Figure 7: 7MM, Diagnosed Prevalent Cases of SSc Classified as lSSc and dSSc, Both Sexes, Age ≥18 Years, N, 2014 52

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[全身性強皮症(強皮症)の疫学的予測]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。H&I文字はH&Iグローバルリサーチ株式会社の商標(登録第5783645号)です。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。
※当サイトでは2016年05月28日現在 190,338 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆